Since the Inflation Reduction Act (IRA) was passed in 2022, significant discussion has been devoted to its potential consequences for the development of new drugs. This report examines whether the IRA has had immediate impacts on drug development in the first half of 2023 through analysis of the companies’ R&D investments and M&A and licensing activities.
Read More
Read More